FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for CAMZYOS (mavacamten) from Myokardia, Inc., marking an approved update to its labeling or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy
• Obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

SUPPL AP for CAMZYOS (MAVACAMTEN)